



### Calibration & Validation Group

Mission: To partner with industrial, academic and regulatory bodies to provide education and forums for discussion of calibration and validation practices throughout the nation

November 22, 2000

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane  
Rm. 1061  
Rockville, MD 20852

**Re: (Docket No. 00D-1424) Draft Guidance for Industry on Analytical Procedures  
and Methods Validation: Chemistry, Manufacturing, and Controls  
Documentation**

The Calibration & Validation Group (CVG) is pleased to have the opportunity to comment on the draft guidance. CVG is a non-profit discussion group formed by over 800 scientists from the pharmaceutical industry, chemical industry, academia and government agencies in Canada. Our objectives include promotion of instrument calibration and method validation in the laboratory and to increase awareness of cGMP's/GLP's. We would like to thank FDA for providing guidance with respect to analytical procedures validation.

To further assist the FDA in the development of the draft guidance, we have organized a Workshop to discuss this guidance document on October 23. We are attaching the summary of the comments with rationale on a line by line basis for the draft guidance issued August 2000. If you have any question, please do not hesitate to contact me at (416)693-3724.

Thank you.

Yours sincerely,

Chung Chow Chan, Ph.D.  
President, CVG

00D-1424

C8

**CVG Workshop on FDA Guidance for Analytical Procedures and Methods Validation October 23  
2000**

line Number	Section	Comments	Proposals
Title		Wording of title	Define "analytical procedures" and "methods" in glossary. Are methods and analytical procedures different?
120-130	III	By definition, "stability indicating" should only need to examine degradation products and will not include process impurities, excipients, etc	Line 124-125 will read: "...measures active ingredients, without interference from degradation products and process impurities. Excipients, or other potential impurities will be assayed as desired".
137	IV	Other official sources of Reference Standards?	Need a complete list of other official reference standards.
149	IV	"...ensure suitability of the reference standard." What does this mean? Possible example of suitability: free base vs. HCl salt. Fine for potency test but not for ID.	"....the user should ensure the suitability of the reference standard if used for something other than its intended use."
Sections V and VI		Contents do not flow well in this order.	Section VII should come immediately after Section V. Section XI should come immediately after Section VI.
237	VI	Are there other examples of acceptable methods sources other than AOAC?	Include a full list of other method sources in an Appendix.
246-249	VI	More detail description of what is expected of the method and why.	Elaborate on the principles e.g. is it for potency, impurities, etc.
251	VI	Need to be precise on the samples.	USP gives exact numbers of how many tablets are required for certain tests. This document is unclear concerning the analysis procedure e.g. 3 injections from one sample or 3 different samples from the original composite.
251-255	VI	More information of sampling is required in this section.	The sample should reflect the true composition of the batch to avoid bias.
321-345	VI	Impurities recommendation is not similar to ICH suggestions. "Total impurities" penalized groups with very low quantitation limit.	Line 331 (#3) should read "any unspecified impurities at or above their QL".
323	VI	Remove retention time (RT) as location/ID for impurities. Retention times can change with dwell volume and is not appropriate for cross chromatogram comparisons for ID.	Remove RT as option. RRT is more appropriate.
441-443	VII	"drug substance" and "active ingredient" used interchangeably throughout document. It will be better to stay with one consistent	In this case replace with "...photolysis, oxidation) for the drug substance and drug substance in the formulation

**CVG Workshop on FDA Guidance for Analytical Procedures and Methods Validation October 23  
2000**

		terminology.	should be provided..."
444	VII	Delete the whole sentence. Previous sentence with "demonstrate specificity" is redundant to sentence in line 444 with "...do not interfere with quantitation of the active"	Delete the whole sentence: "The stress studies that should demonstrate.....do not interfere with the quantitation of the active ingredient".
723	X	"Sample of impurities" need to be defined.	Major named impurities or major named degradation products to replace "sample of impurities".
	XI(F) and VI(B)	There is a lack of sampling requirements for particle size. Sampling should be representative of batch and do not introduce bias. This is important and to be mentioned up front.	A note should be added to include sampling specifically for particle size analyzer.
	XI	Add in a section on wet chemistry analysis e.g. Titration or Karl Fisher.	KF is an important attribute of pharmaceutical analysis and should be included. Include this in Section XI under "Titration techniques". This section will complement the existing section in USP.
821	XI	Replace the word 'plastic' with 'polymer'.	More scientific expression.
823	XI	"Frit size" is not a useful column parameter.	Remove "frit size" from list of column parameters.
846	XI	Capacity factor is difficult to determine and not accurate & useful.	Remove capacity factor.
866-871	XI	The type of mixing can adversely affect HPLC runs with a mobile phase gradient.	Add sentence regarding possibility of additional parameters being examined e.g. low or high pressure mixing during mobile phase gradient.
973	XI	Optical rotation is not sufficiently sensitive for measuring enantiomeric purity of compounds with small optical rotation. The method is generally useful for establishing enantiomeric identity.	Replace 1 <sup>st</sup> sentence with "Optical rotation is used for establishing enantiomeric identity and may be used for measuring enantiomeric purity".
998-1035	XI	Not listing the operating parameters of particle analyzer	List the model made of the instrument as the analyses of particle size are instrument specific.
998, 1000, 1005, 1009 and 1011	XI (F)	There are many characteristic studied than just 'particle size' alone	Replace title in line 998 of "Methodologies Relating to Particle Size Analysis" with "Methodologies Relating to Particle Characterization".
1026	XI	Size exclusion chromatography. It does not really belong as it is more of a 'molecular study'.	Remove "size exclusion chromatography".
1066	XI	The validation of the dissolution	Define dissolution procedures

**CVG Workshop on FDA Guidance for Analytical Procedures and Methods Validation October 23  
2000**

		technique need to be differentiated from the validation of the analysis of the samples.	e.g. paddle vs. basket, medium used, or rpm. Clearly define components of dissolution procedure that need validation,  <b>or alternatively,</b>  Change the sentence to read "Dissolution procedure should be justified and the method of analysis should be validated".
1108-9, 1115, 1118	Attachment A	Reference is not correct	1108: Section VII.A 2.b not c 1109: Section VII.A.2.c not b. 1115: Should be Section X
1108, 1116 and 1122	Attachment A	Reduce duplication of stress study information in different places of the submission.	Consolidate a section on Stress Study e.g. 'Degradation Information from Stress Studies' in the submission document.



Combined Customs Invoice / Shipment Air Waybill  
Facture des Douanes / Connaissance aérien de l'envoi  
(Non negotiable) / (Non négociable)

7314760493

ORIGIN/ORIGINE  
DESTINATION  
GAL

1 From (Sender) / Expéditeur

Account no./N° de compte  
Sender's name/Nom de l'expéditeur  
770456297

Sender's references first twelve characters will be shown on invoice  
Références de l'expéditeur les douze premiers caractères apparaîtront sur la facture

ELI LILLY INC  
6650 DANFORTH AVE  
SCARBOROUGH, ON

Postal code/Code postal  
M1N 2E2  
Phone/Fax/Telex, specify one  
416-693-3683

2 To (Receiver) / Destinataire (réceptionnaire)

FOOD DRUG ADMINISTRATION  
5630 FRIARS LANE  
ROOM 1061  
ROCKVILLE, MD 20852

Postal code/Code postal  
20852  
USA

Contact person/Personne-ressource  
Docket # 1000-1424  
Phone/Fax/Telex, specify one  
Telephone/télécopier/telex indiquer lequel.


5 Sender's authorization and signature/Autorisation et signature de l'expéditeur

I/we agree that DHL's standard terms apply to this shipment and limit DHL's liability. The Warsaw Convention may also apply (see reverse).  
J'accepte (nous acceptons) que les modalités standard de DHL s'appliquent à cet envoi et limitent la responsabilité de DHL. La Convention de Varsovie peut aussi s'appliquer (voir l'endos).  
I/we understand that DHL does not transport cash or dangerous goods (see reverse). Je comprends/nous comprenons que DHL ne transporte pas d'argent ou de marchandises dangereuses (voir l'endos).

Signature  
Date 11/23/00

PRINTED IN USA

Quote this shipment number in an enquiry/Indiquez ce numéro d'envoi lors d'une demande



3 Shipment details / Détails sur l'envoi

Not all payment and service options are available in all countries.  
Certaines options de paiement et de service ne sont pas disponibles dans tous les pays.

Services  
☐ DOCUMENT  
☐ WORLDWIDE PARCEL EXPRESS  
All declarable/ tous les envois à déclarer  
☐ EXPRESS DOCUMENT (Max. 650gm)  
DOCUMENT EXPRESS 220 g max  
☐ WORLDMAIL  
☐ OTHER SERVICE  
AUTRE SERVICE  
specify/ spécifier  
Transport charges/Frais de transport  
If left blank sender pays transport charges  
Si laissé blanc, l'expéditeur devra acquiescer les frais de transport.  
☒ Sender/Expéditeur  
☐ Cash/Cheque/Credit Card  
Comptant/cheque/carte de crédit  
For approved customers only  
Pour comptes approuvés seulement  
☐ External Billing Agreement  
Entente de facturation extérieure  
☐ Transport collect/Transport port dû

Shipment insurance see reverse  
Assurance sur l'envoi voir l'endos  
☐ YES  
☐ NO

Full description of contents/Description complète du contenu

DOCUMENT

Country of manufacture  
Pays de fabrication  
International Worldwide Parcel Express shipments only/Envois Worldwide Parcel Express à destination internationale

Declared value  
Valeur déclarée  
Sender's VAT/GST No.  
N° de TPS/TVA de l'expéditeur

Harmonised commodity code if applies  
Code harmonisé de marchandises le cas échéant  
Receiver's VAT/GST No. or EIN/SSN  
N° de TPS/TVA ou EIN/SSN du destinataire

Type of export  
Type d'exportation  
☐ PERMANENT  
PERMANENTE  
☐ REPAIR/RETURN  
REPARATION/RETOUR  
☐ TEMPORARY  
TEMPORAIRE

Destination duties/Taxes If left blank receiver pays duties/taxes  
Droits et taxes à destination. Si laissé blanc, le destinataire devra payer les droits et taxes.  
☐ Receiver  
Destinataire  
☒ Sender  
Expéditeur  
☐ Other  
Autre  
Specify destination approved account number  
Indiquer le numéro de compte destinataire approuvé

4 Size and weight/Taille et poids

No. of pieces  
Nbre de pièces  
1  
Weight/Poids  
1.00 kg  
Dimensions cm L x W x H  
Dimensions cm L x W x H

VOLUMETRIC/CHARGED WEIGHT  
POIDS VOLUMETRIQUE/FACTURE

CODES  
CHARGES/FRAIS  
Services/Services  
Special / Spéciaux  
Insurance / Assurance  
Other/VAT / Autre/TVA

CURRENCY CODE  
CODE DE DEVISE  
TOTAL

TRANSPORT COLLECT STICKER No.  
TRANSPORT PORT DÛ N°

PICKED UP BY/RAMASSÉ PAR

Route No.  
1023  
Time  
11:23 AM  
Date  
NOV 23 2000

Complete parts 1-5. You are making 5 copies, please type.  
Remplissez les sections 1 à 5. Vous faites 5 copies - veuillez dactylographier.  
Destination Copy / Copie de Destination